A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses

Vaccine

Volumn 30, Issue 15, 2012, Pages 2570-2581

  Xiao, Liang ^a   Kim, Jocelyn ^b   Lim, Matthew ^a   Dai, Bingbing ^a   Yang, Lili ^b   Reed, Steven G ^c   Baltimore, David ^b   Wang, Pin ^a,d  

^a University of Southern California ^*  (United States)

^b CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^c INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Adjuvant; Dendritic cells; Lentiviral vector; MyD88; TLR4 agonist; TRIF

Indexed keywords

DENDRITIC CELL LENTIVIRUS VECTOR; GLUCOPYRANOSYL LIPID A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOLOGICAL ADJUVANT; LENTIVIRUS VECTOR; MYELOID DIFFERENTIATION FACTOR 88; OVALBUMIN; PLASMID VECTOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW CELL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ADJUVANTS, IMMUNOLOGIC; ANIMALS; DENDRITIC CELLS; FEMALE; GENETIC VECTORS; IMMUNITY, HUMORAL; LENTIVIRUS; LIPID A; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 4;

EID: 84862817112     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.074     Document Type: Article

References (87)

1. Hu B., Tai A., Wang P. Immunization delivered by lentiviral vectors for cancer and infectious diseases. Immunol Rev 2011, 239(1):45-61.
2. He Y., Munn D., Falo L.D. Recombinant lentivector as a genetic immunization vehicle for antitumor immunity. Expert Rev Vaccines 2007, 6(6):913-924.
3. He Y., Falo L.D. Lentivirus as a potent and mechanistically distinct vector for genetic immunization. Curr Opin Mol Ther 2007, 9(5):439-446.
4. Pincha M., Sundarasetty B.S., Stripecke R. Lentiviral vectors for immunization: an inflammatory field. Expert Rev Vaccines 2010, 9(3):309-321.
5. Draper S.J., Heeney J.L. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 2010, 8(1):62-73.
6. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272(5259):263-267.
7. Kootstra N.A., Verma I.M. Gene therapy with viral vectors. Annu Rev Pharmacol Toxicol 2003, 43:413-439.
8. Escors D., Breckpot K. Lentiviral vectors in gene therapy: their current status and future potential. Arch Immunol Ther Exp 2010, 58(2):107-119.
9. Breckpot K., Aerts J.L., Thielemans K. Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther 2007, 14(11):847-862.
10. Sigel M.B., Sinha Y.N., VanderLaan W.P. Production of antibodies by inoculation into lymph nodes. Methods Enzymol 1983, 93:3-12.
11. Maloy K.J., Erdmann I., Basch V., Sierro S., Kramps T.A., Zinkernagel R.M., et al. Intralymphatic immunization enhances DNA vaccination. Proc Natl Acad Sci USA 2001, 98(6):3299-3303.
12. Senti G., Johansen P., Kundig T.M. Intralymphatic immunotherapy. Curr Opin Allergy Clin Immunol 2009, 9(6):537-543.
13. He Y., Zhang J., Donahue C., Falo L.D. Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity 2006, 24(5):643-656.
14. Furmanov K., Elnekave M., Lehmann D., Clausen B.E., Kotton D.N., Hovav A.H. The role of skin-derived dendritic cells in CD8+ T cell priming following immunization with lentivectors. J Immunol 2010, 184(9):4889-4897.
15. Goold H.D., Escors D., Conlan T.J., Chakraverty R., Bennett C.L. Conventional dendritic cells are required for the activation of helper-dependent CD8 T cell responses to a model antigen after cutaneous vaccination with lentiviral vectors. J Immunol 2011, 186(8):4565-4572.
16. Lopes L., Dewannieux M., Gileadi U., Bailey R., Ikeda Y., Whittaker C., et al. Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses. J Virol 2008, 82(1):86-95.
17. Kimura T., Koya R.C., Anselmi L., Sternini C., Wang H.J., Comin-Anduix B., et al. Lentiviral vectors with CMV or MHCII promoters administered in vivo: immune reactivity versus persistence of expression. Mol Ther 2007, 15(7):1390-1399.
18. Dresch C., Edelmann S.L., Marconi P., Brocker T. Lentiviral-mediated transcriptional targeting of dendritic cells for induction of T cell tolerance in vivo. J Immunol 2008, 181(7):4495-4506.
19. Ageichik A., Buchholz C.J., Collins M.K. Lentiviral vectors targeted to MHC II are effective in immunization. Hum Gene Ther 2011, 22(10):1249-1254.
20. Ageichik A., Collins M.K., Dewannieux M. Lentivector targeting to dendritic cells. Mol Ther 2008, 16(6):1008-1009.
21. Goyvaerts C., De Groeve K., Dingemans J., Van Lint S., Robays L., Heirman C., et al. Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells. Gene Ther 2012, 10.1038/gt.2011.206.
22. Verhoeyen E., Cosset F.L. Engineering the surface glycoproteins of lentiviral vectors for targeted gene transfer. Cold Spring Harbor Protoc 2009, 2009(8):pdb top59.
23. Yang L., Yang H., Rideout K., Cho T., Joo K.I., Ziegler L., et al. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol 2008, 26(3):326-334.
24. Yang H., Hu B., Xiao L., Wang P. Dendritic cell-directed lentivector vaccine induces antigen-specific immune responses against murine melanoma. Cancer Gene Ther 2011, 18(5):370-380.
25. Dai B., Yang L., Yang H., Hu B., Baltimore D., Wang P. HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells. Proc Natl Acad Sci USA 2009, 106(48):20382-20387.
26. Hu B., Dai B., Wang P. Vaccines delivered by integration-deficient lentiviral vectors targeting dendritic cells induces strong antigen-specific immunity. Vaccine 2010, 28(41):6675-6683.
27. Breckpot K., Escors D., Arce F., Lopes L., Karwacz K., Van Lint S., et al. HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7. J Virol 2010, 84(11):5627-5636.
28. Breckpot K., Emeagi P., Dullaers M., Michiels A., Heirman C., Thielemans K. Activation of immature monocyte-derived dendritic cells after transduction with high doses of lentiviral vectors. Hum Gene Ther 2007, 18(6):536-546.
29. Tan P.H., Beutelspacher S.C., Xue S.A., Wang Y.H., Mitchell P., McAlister J.C., et al. Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood 2005, 105(10):3824-3832.
30. Janeway C.A., Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002, 20:197-216.
31. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124(4):783-801.
32. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004, 5(10):987-995.
33. Lee H.K., Iwasaki A. Innate control of adaptive immunity: dendritic cells and beyond. Semin Immunol 2007, 19(1):48-55.
34. Iwasaki A., Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010, 327(5963):291-295.
35. Lu Y.C., Yeh W.C., Ohashi P.S. LPS/TLR4 signal transduction pathway. Cytokine 2008, 42(2):145-151.
36. Shen H., Tesar B.M., Walker W.E., Goldstein D.R. Dual signaling of MyD88 and TRIF is critical for maximal TLR4-induced dendritic cell maturation. J Immunol 2008, 181(3):1849-1858.
37. Baldridge J.R., Crane R.T. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods 1999, 19(1):103-107.
38. Qureshi N., Kaltashov I., Walker K., Doroshenko V., Cotter R.J., Takayama K., et al. Structure of the monophosphoryl lipid A moiety obtained from the lipopolysaccharide of Chlamydia trachomatis. J Biol Chem 1997, 272(16):10594-10600.
39. Evans J.T., Cluff C.W., Johnson D.A., Lacy M.J., Persing D.H., Baldridge J.R. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev Vaccines 2003, 2(2):219-229.
40. Reed S.G., Bertholet S., Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009, 30(1):23-32.
41. Coler R.N., Bertholet S., Moutaftsi M., Guderian J.A., Windish H.P., Baldwin S.L., et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS ONE 2011, 6(1):e16333.
42. Baldwin S.L., Bertholet S., Kahn M., Zharkikh I., Ireton G.C., Vedvick T.S., et al. Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine 2009, 27(23):3063-3071.
43. Bertholet S., Goto Y., Carter L., Bhatia A., Howard R.F., Carter D., et al. Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine 2009, 27(50):7036-7045.
44. Baldwin S.L., Shaverdian N., Goto Y., Duthie M.S., Raman V.S., Evers T., et al. Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 2009, 27(43):5956-5963.
45. Lousada-Dietrich S., Jogdand P.S., Jepsen S., Pinto V.V., Ditlev S.B., Christiansen M., et al. A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 - a GLURP-MSP3 fusion protein malaria vaccine candidate. Vaccine 2011, 29(17):3284-3292.
46. Lumsden J.M., Pichyangkul S., Srichairatanakul U., Yongvanitchit K., Limsalakpetch A., Nurmukhambetova S., et al. Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic TLR4 agonist formulated in an emulsion. Infect Immun 2011, 79(9):3492-3500.
47. Coler R.N., Baldwin S.L., Shaverdian N., Bertholet S., Reed S.J., Raman V.S., et al. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS ONE 2010, 5(10):e13677.
48. Rowe H.M., Lopes L., Ikeda Y., Bailey R., Barde I., Zenke M., et al. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene. Mol Ther 2006, 13(2):310-319.
49. Lois C., Hong E.J., Pease S., Brown E.J., Baltimore D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 2002, 295(5556):868-872.
50. Andreakos E., Williams R.O., Wales J., Foxwell B.M., Feldmann M. Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant. Proc Natl Acad Sci USA 2006, 103(39):14459-14464.
51. Song X.T., Evel-Kabler K., Shen L., Rollins L., Huang X.F., Chen S.Y. A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat Med 2008, 14(3):258-265.
52. Stephens G.L., McHugh R.S., Whitters M.J., Young D.A., Luxenberg D., Carreno B.M., et al. Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J Immunol 2004, 173(8):5008-5020.
53. Thornton A.M., Shevach E.M. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 2000, 164(1):183-190.
54. Makino Y., Cook D.N., Smithies O., Hwang O.Y., Neilson E.G., Turka L.A., et al. Impaired T cell function in RANTES-deficient mice. Clin Immunol 2002, 102(3):302-309.
55. O'Sullivan B.J., Thomas H.E., Pai S., Santamaria P., Iwakura Y., Steptoe R.J., et al. IL-1 beta breaks tolerance through expansion of CD25+ effector T cells. J Immunol 2006, 176(12):7278-7287.
56. Nakae S., Asano M., Horai R., Iwakura Y. Interleukin-1 beta, but not interleukin-1 alpha, is required for T-cell-dependent antibody production. Immunology 2001, 104(4):402-409.
57. Dufour J.H., Dziejman M., Liu M.T., Leung J.H., Lane T.E., Luster A.D. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 2002, 168(7):3195-3204.
58. Angiolillo A.L., Sgadari C., Taub D.D., Liao F., Farber J.M., Maheshwari S., et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995, 182(1):155-162.
59. Fagarasan S., Honjo T. Intestinal IgA synthesis: regulation of front-line body defences. Nat Rev Immunol 2003, 3(1):63-72.
60. Shedlock D.J., Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003, 300(5617):337-339.
61. Sun J.C., Bevan M.J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003, 300(5617):339-342.
62. Janssen E.M., Droin N.M., Lemmens E.E., Pinkoski M.J., Bensinger S.J., Ehst B.D., et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 2005, 434(7029):88-93.
63. Janssen E.M., Lemmens E.E., Wolfe T., Christen U., von Herrath M.G., Schoenberger S.P. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003, 421(6925):852-856.
64. Smith C., Martinez M., Cooper L., Rist M., Zhong J., Khanna R. Generating functional CD8+ T cell memory response under transient CD4+ T cell deficiency: implications for vaccination of immunocompromised individuals. Eur J Immunol 2008, 38(7):1857-1866.
65. Mata-Haro V., Cekic C., Martin M., Chilton P.M., Casella C.R., Mitchell T.C. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007, 316(5831):1628-1632.
66. Beignon A.S., Mollier K., Liard C., Coutant F., Munier S., Riviere J., et al. Lentiviral vector-based prime/boost vaccination against AIDS: pilot study shows protection against Simian immunodeficiency virus SIVmac251 challenge in macaques. J Virol 2009, 83(21):10963-10974.
67. Escors D., Lopes L., Lin R., Hiscott J., Akira S., Davis R.J., et al. Targeting dendritic cell signaling to regulate the response to immunization. Blood 2008, 111(6):3050-3061.
68. Breckpot K., Escors D. Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification. Endocr Metab Immune Disord Drug Targets 2009, 9(4):328-343.
69. Arce F., Kochan G., Breckpot K., Stephenson H., Escors D. Selective activation of intracellular signalling pathways in dendritic cells for cancer immunotherapy. Anticancer Agents Med Chem 2011, Jun 27, [Epub ahead of print].
70. Yang Y., Huang C.T., Huang X., Pardoll D.M. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 2004, 5(5):508-515.
71. Lang K.S., Recher M., Junt T., Navarini A.A., Harris N.L., Freigang S., et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med 2005, 11(2):138-145.
72. Gautier G., Humbert M., Deauvieau F., Scuiller M., Hiscott J., Bates E.E., et al. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med 2005, 201(9):1435-1446.
73. Napolitani G., Rinaldi A., Bertoni F., Sallusto F., Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005, 6(8):769-776.
74. Warger T., Osterloh P., Rechtsteiner G., Fassbender M., Heib V., Schmid B., et al. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 2006, 108(2):544-550.
75. Breckpot K., Dullaers M., Bonehill A., van Meirvenne S., Heirman C., de Greef C., et al. Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med 2003, 5(8):654-667.
76. Esslinger C., Chapatte L., Finke D., Miconnet I., Guillaume P., Levy F., et al. In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest 2003, 111(11):1673-1681.
77. Reis e Sousa C., Stahl P.D., Austyn J.M. Phagocytosis of antigens by Langerhans cells in vitro. J Exp Med 1993, 178(2):509-519.
78. Garrett W.S., Chen L.M., Kroschewski R., Ebersold M., Turley S., Trombetta S., et al. Developmental control of endocytosis in dendritic cells by Cdc42. Cell 2000, 102(3):325-334.
79. Guermonprez P., Valladeau J., Zitvogel L., Thery C., Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002, 20:621-667.
80. Karwacz K., Bricogne C., MacDonald D., Arce F., Bennett C.L., Collins M., et al. PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Mol Med 2011, 3(10):581-592.
81. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000, 6(4):443-446.
82. Dullaers M., Van Meirvenne S., Heirman C., Straetman L., Bonehill A., Aerts J.L., et al. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther 2006, 13(7):630-640.
83. Johnson S., Zhan Y., Sutherland R.M., Mount A.M., Bedoui S., Brady J.L., et al. Selected Toll-like receptor ligands and viruses promote helper-independent cytotoxic T cell priming by upregulating CD40L on dendritic cells. Immunity 2009, 30(2):218-227.
84. Bennett S.R., Carbone F.R., Karamalis F., Miller J.F., Heath W.R. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med 1997, 186(1):65-70.
85. Ridge J.P., Di Rosa F., Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998, 393(6684):474-478.
86. Xiang J., Huang H., Liu Y. A new dynamic model of CD8+ T effector cell responses via CD4+ T helper-antigen-presenting cells. J Immunol 2005, 174(12):7497-7505.
87. Cekic C., Casella C.R., Eaves C.A., Matsuzawa A., Ichijo H., Mitchell T.C. Selective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid A. J Biol Chem 2009, 284(46):31982-31991.